1628618-35-8 Usage
Chemical class
Pyrrolopyridine derivatives
Triazolopyridinyl-ethyl group
A 2-ethyl group attached to a [1,2,4]triazolo[1,5-a]pyridin-2-yl moiety
Chloro-methyl group
A 7-chloro (Cl) substituent on the pyrrolopyridine core
Dihydrodione moiety
A 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-1,6(5H)-dione group
Molecular structure
The compound has a complex structure with multiple fused rings and various substituents
Pharmacological properties
Potential for therapeutic applications due to its unique structure
Medicinal chemistry potential
The compound may be used in the development of new drug molecules
Drug discovery research
Its chemical properties make it a candidate for further investigation in drug discovery
Molecular weight
329.77 g/mol
Check Digit Verification of cas no
The CAS Registry Mumber 1628618-35-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,8,6,1 and 8 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1628618-35:
(9*1)+(8*6)+(7*2)+(6*8)+(5*6)+(4*1)+(3*8)+(2*3)+(1*5)=188
188 % 10 = 8
So 1628618-35-8 is a valid CAS Registry Number.
1628618-35-8Relevant articles and documents
NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
-
, (2014/09/29)
The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
